Barclays Boosts Aveanna Healthcare (NASDAQ:AVAH) Price Target to $11.00

Aveanna Healthcare (NASDAQ:AVAH) had its price objective increased by investment analysts at Barclays from $9.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 19.31% from the company’s previous close.

Several other equities analysts also recently commented on the stock. Raymond James Financial restated an “outperform” rating and issued a $13.00 price target on shares of Aveanna Healthcare in a research note on Friday, December 5th. Jefferies Financial Group boosted their target price on Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. JPMorgan Chase & Co. upgraded Aveanna Healthcare from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $6.00 to $10.00 in a report on Thursday, September 18th. Royal Bank Of Canada lifted their price objective on Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.06.

Aveanna Healthcare Stock Performance

NASDAQ AVAH opened at $9.22 on Friday. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. The company has a market cap of $1.93 billion, a P/E ratio of 25.61 and a beta of 2.06. The stock has a 50-day moving average of $8.83 and a two-hundred day moving average of $7.78. Aveanna Healthcare has a 1-year low of $3.67 and a 1-year high of $10.32.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08. The business had revenue of $621.94 million for the quarter, compared to analysts’ expectations of $578.57 million. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. As a group, analysts anticipate that Aveanna Healthcare will post -0.06 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Paul R. Vigano sold 10,000,000 shares of the stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $9.00, for a total value of $90,000,000.00. Following the transaction, the insider directly owned 386,284 shares of the company’s stock, valued at $3,476,556. This trade represents a 96.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total transaction of $230,452.45. Following the sale, the chief executive officer owned 2,394,179 shares in the company, valued at $18,794,305.15. This represents a 1.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,857,606 shares of company stock valued at $295,491,307 over the last three months. 7.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aveanna Healthcare

Hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at about $43,000. Diversified Trust Co purchased a new position in shares of Aveanna Healthcare during the second quarter worth approximately $57,000. MQS Management LLC acquired a new position in shares of Aveanna Healthcare in the 2nd quarter valued at $59,000. Belvedere Trading LLC purchased a new stake in Aveanna Healthcare in the 2nd quarter valued at $62,000. Finally, Oxford Asset Management LLP acquired a new stake in Aveanna Healthcare during the 2nd quarter worth $64,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.